Resources

Shigella is the leading bacterial cause of childhood diarrhea, and infections can have long-term effects on growth and development. No licensed Shigella vaccines currently exist, but several promising candidates in development could become available in a few years.PATH conducted a series of studies to better understand the public health value of potential Shigella vaccines and help inform decisions by international agencies, funders, vaccine developers, and national policymakers. This included: vaccine impact and cost-effectiveness analyses, demand forecasts for two potential markets, an expert consultation on Shigella-containing combination vaccines, and a feasibility and acceptability study with national stakeholders and healthcare providers in five countries. This brief provides a comprehensive summary of the results.

PATH helps policymakers and advocates make evidence-based policy and funding decisions to advance health equity. Leveraging PATH's nearly 50 years of experience developing and delivering health innovations and services for women and children, our advocates collect, analyze, package, and use data to inform policies, mobilize resources, engage citizens, and hold decision-makers accountable. This fact sheet details how PATH is driving change at the intersection of advocacy and technical assistance to help women and children around the world survive and thrive.

User research in low-resource primary health care settings to inform decisions, and better understand and define user and health system constraints related to integrating smartphones and multimodal devices into integrated management of childhood illness (IMCI) practices.

This fact sheet provides an overview of the novel oral polio vaccine (nOPV) program—a consortium of PATH and partners that are working to advance novel vaccine candidates that will enable complete eradication and minimize the risk of polio resurgence.

This report present’s PATH’s Living Labs synthesis of insights including gaps, trends, findings, and recommendations for primary healthcare in Ghana, Kenya, Nigeria, Rwanda, Tanzania, and Zambia conducted between January and March 2023.